Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial

Compass Therapeutics (NASDAQ:CMPX) was upgraded by analysts at Raymond James Financial to an “outperform” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a $9.00 price objective on the stock. Raymond James Financial’s price objective indicates a potential upside of 243.51% from the company’s previous close.

CMPX has been the topic of several other research reports. D. Boral Capital reissued a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 28th. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Guggenheim cut their price target on Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $12.67.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.62 on Tuesday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The firm has a market cap of $362.29 million, a price-to-earnings ratio of -6.39 and a beta of 1.48. The company has a fifty day moving average price of $2.19 and a 200-day moving average price of $2.27.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). On average, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider directly owned 21,000 shares in the company, valued at approximately $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently bought and sold shares of the business. Enavate Sciences GP LLC purchased a new position in Compass Therapeutics in the 4th quarter worth approximately $11,293,000. Tang Capital Management LLC raised its position in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after buying an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC lifted its holdings in shares of Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 138.2% during the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company’s stock worth $1,787,000 after acquiring an additional 545,767 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Compass Therapeutics during the first quarter worth $579,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.